Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters











Database
Language
Publication year range
1.
Indian J Dermatol Venereol Leprol ; 84(3): 251-262, 2018.
Article in English | MEDLINE | ID: mdl-29516900

ABSTRACT

Herpes zoster is a major health burden that can affect individuals of any age. It is seen more commonly among individuals aged ≥50 years, those with immunocompromised status, and those on immunosuppressant drugs. It is caused by a reactivation of varicella zoster virus infection. Cell-mediated immunity plays a role in this reactivation. Fever, pain, and itch are common symptoms before the onset of rash. Post-herpetic neuralgia is the most common complication associated with herpes zoster. Risk factors and complications associated with herpes zoster depend on the age, immune status, and the time of initializing treatment. Routine vaccination for individuals over 60 years has shown considerable effect in terms of reducing the incidence of herpes zoster and post-herpetic neuralgia. Treatment with antiviral drugs and analgesics within 72 hours of rash onset has been shown to reduce severity and complications associated with herpes zoster and post-herpetic neuralgia. This study mainly focuses on herpes zoster using articles and reviews from PubMed, Embase, Cochrane library, and a manual search from Google Scholar. We cover the incidence of herpes zoster, gender distribution, seasonal and regional distribution of herpes zoster, incidence of herpes zoster among immunocompromised individuals, incidence of post-herpetic neuralgia following a zoster infection, complications, management, and prevention of herpes zoster and post-herpetic neuralgia.


Subject(s)
Antiviral Agents/administration & dosage , Herpes Zoster/epidemiology , Herpes Zoster/therapy , Neuralgia, Postherpetic/epidemiology , Neuralgia, Postherpetic/therapy , Adrenal Cortex Hormones/administration & dosage , Electric Stimulation Therapy/methods , Herpes Zoster/prevention & control , Humans , Immunocompromised Host/drug effects , Immunocompromised Host/physiology , Incidence , Neuralgia, Postherpetic/prevention & control , Risk Factors , Sex Factors , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL